publication venue for
- Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study. Volume 18:2933-2953. 2023
- Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review. Volume 18:719-731. 2023
- COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Volume 18:407-418. 2023
- Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Volume 18:2039-2054. 2023
- Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Volume 18:643-659. 2023
- Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. Volume 18:1431-1444. 2023
- Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. Volume 18:1815-1825. 2023
- Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK. Volume 18:2673-2685. 2023
- Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Volume 18:231-245. 2023
- Associations with Post-Consultation Health-Status in Primary Care Managed Acute Exacerbation of COPD. Volume 17:383-394. 2022
- Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation. Volume 17:491-504. 2022
- Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Volume 17:1455-1466. 2022
- Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England. Volume 17:1781-1795. 2022
- Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain. Volume 17:2161-2174. 2022
- Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Volume 17:2417-2429. 2022
- Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. Volume 17:3097-3109. 2022
- Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. Volume 17:2745-2755. 2022
- Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. Volume 17:415-426. 2022
- Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. Volume 17:1633-1642. 2022
- Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. Volume 16:3105-3118. 2021
- Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. Volume 16:1621-1636. 2021
- Feasibility of a 6-Month Home-Based Fall Prevention Exercise Program in Older Adults with COPD. Volume 16:1569-1579. 2021
- Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Volume 16:2591-2604. 2021
- Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. Volume 16:2795-2808. 2021
- Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. Volume 16:1255-1264. 2021
- Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. Volume 16:321-332. 2021
- <p>Clinical Features and C-Reactive Protein as Predictors of Bacterial Exacerbations of COPD</p>. Volume 15:3147-3158. 2020
- <p>Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective</p>. Volume 15:1621-1632. 2020
- <p>Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review</p>. Volume 15:439-460. 2020
- <p>Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany</p>. Volume 15:595-604. 2020
- <p>Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review</p>. Volume 15:417-438. 2020
- <p>Which Balance Subcomponents Distinguish Between Fallers and Non-Fallers in People with COPD?</p>. Volume 15:1557-1564. 2020
- <p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p>. Volume 14:2681-2695. 2019
- <p>Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease</p>. Volume 14:2121-2129. 2019
- <p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p>. Volume 14:939-951. 2019
- <p>Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study</p>. Volume 14:249-260. 2019
- COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. Volume 14:51-63. 2019
- Prevalence of osteoarthritis in individuals with COPD: a systematic review. Volume 13:1207-1216. 2018
- Colds as predictors of the onset and severity of COPD exacerbations. Volume 12:839-848. 2017
- The role of pain in pulmonary rehabilitation: a qualitative study. Volume 12:3289-3299. 2017
- The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Volume 12:59-71. 2017
- Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β<sub>2</sub>-agonist fixed-dose combination: RE<sup>2</sup>SPOND rationale and study design. Volume 11:1921-1928. 2016
- Validity of COPD diagnoses reported through nationwide health insurance systems in the People’s Republic of China. 11:419-419. 2016
- COPD and its association with smoking in the Mainland China: a cross-sectional analysis of 0.5 million men and women from ten diverse areas. 10:655-655. 2015
- Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. 10:1863-1863. 2015
- Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. 10:2495-2495. 2015
- The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. 10:2207-2207. 2015
- Optimizing nonpharmacological management following an acute exacerbation of chronic obstructive pulmonary disease. 9:1197-1197. 2014